Trials / Completed
CompletedNCT03050710
Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds
A Prospective, Open-label, Multicenter, Post-market Study Evaluating Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Croma-Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® VOLUME Lidocaine and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator.
Detailed description
This is a prospective, open label, multicenter, post-market investigation. Following informed consent and screening, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® VOLUME Lidocaine, and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator. The performance of the investigational device will be evaluated by the investigator by assessing severity of nasolabial folds using the Nasolabial Folds Severity Rating Scale (NLF-SRS) (4, 24 and 36 weeks after the treatment and in comparison to Day 0), global aesthetic improvement (4, 24 and 36 weeks after the treatment). The subject will evaluate pain intensity associated with the treatment (at Day 0 and at Week 2 (if Touch-up treatment occurred)), and satisfaction with the treatment 4, 24 and 36 weeks after the treatment. The safety will be evaluated based on occurrence of adverse events, which will be collected throughout the investigation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Princess® VOLUME Lidocaine | Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable |
Timeline
- Start date
- 2016-12-27
- Primary completion
- 2017-07-18
- Completion
- 2017-10-17
- First posted
- 2017-02-13
- Last updated
- 2025-06-04
- Results posted
- 2025-06-04
Locations
3 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT03050710. Inclusion in this directory is not an endorsement.